
|Articles|July 31, 2017
LabCorp to Acquire Chiltern for Approximately $1.2 Billion
Advertisement
LabCorp-global life sciences company-and specialty CRO, Chiltern, announced that LabCorp will acquire Chiltern in an all-cash transaction for approximately $1.2 billion. Following the completion of the transaction, Chiltern will become part of LabCorp’s Covance segment.
Read the full release
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Meeting Halfway: Co-Developing Frameworks for Seamless FSO to FSP Transitions
2
SCOPE Summit 2026: Where AI Is Making the Most Immediate Impact Across R&D
3
SCOPE Summit 2026: ESG Shifts From Reporting Exercise to Vendor Readiness Test in Clinical Operations
4
Regulatory Uncertainty Emerges Across the Drug Development Lifecycle
5




